ライフサイエンスコーパス: triiodothyronine

1 total and free thyroxine, and total and free triiodothyronine.

2 5'-deiodination of thyroxine to form 3,5,3'-triiodothyronine.

3 roxine (T4) to its active metabolite, 3,5,3'-triiodothyronine.

4 ferase activity by about 90% with or without triiodothyronine.

5 alamus was diminished by coadministration of triiodothyronine.

6 and T4 were suppressed by administration of triiodothyronine.

7 traperitoneal injections of freshly prepared triiodothyronine (0.2 mg x kg(-1) x d(-1)).

8 cultured human epidermal keratinocytes, with triiodothyronine (100 pmol/L) or thyroxine (100 nmol/L).

9 was induced by daily injection of l-3,5, 3'-triiodothyronine (15 ug (100 g)-1) intraperitoneally dai

10 6-dihydroxyindole-2-carboxylic acid, 3,3',5'-triiodothyronine, 3,3',5-triiodothyronine, gentisate, ro

11 ddition, we evaluated the in vitro effect of triiodothyronine, 9-cis-retinoic acid, and the retinoid

12 nal barrier, and (ii) both dexamethasone and triiodothyronine accelerate barrier development.

13 ent with either 10 nM dexamethasone or 10 nM triiodothyronine accelerated SC development and barrier

14 ing concentrations of leptin, thyroxine, and triiodothyronine act coordinately to favor weight regain

15 Triiodothyronine administration prevents decreases in se

16 Triiodothyronine also increased mitochondrial transcript

17 hyronine among women and with total and free triiodothyronine among men in lipid-standardized models.

18 h greater total and free thyroxine and total triiodothyronine among women and with total and free tri

19 as 50 percent, an effect similar to that of triiodothyronine and 9-cis-retinoic acid.

20 orter function is reflected in elevated free triiodothyronine and lowered free thyroxine levels in th

21 terventions described were desmopressin use, triiodothyronine and methylprednisolone replacement, flu

22 for thyroid dysfunction, as serum thyroxine/triiodothyronine and somatic growth were normal.

23 As expected, the serum triiodothyronine and T(4) concentrations decreased in wi

24 However, triiodothyronine and T(4) levels in fasted Car(-/-) mice

25 ormation of (131)I-labeled levothyroxine and triiodothyronine and thereby reduce the protein-bound (1

26 treatment significantly increased uptake of triiodothyronine and thyroxine (4.1- and 4.3-fold, respe

27 Dysregulation of thyroid hormones triiodothyronine and thyroxine (T3/T4) can impact metabo

28 icantly higher circulating concentrations of triiodothyronine and thyroxine at the end of the VLED th

29 could be attributed to decreased circulating triiodothyronine and thyroxine concentrations secondary

30 ssential constituent of the thyroid hormones triiodothyronine and thyroxine, which are required for t

31 differentiation method supplemented with T3 (triiodothyronine) and/or Dex (dexamethasone) during days

32 verts thyroxine to the active hormone 3,5,3'-triiodothyronine, and in the rat is expressed in the bra

33 analysis, changes in skeletal muscle, plasma triiodothyronine, and kidney masses explained 34.9%, 5.3

34 crease in serum levels of thyroxine, reverse triiodothyronine, and thyroid-stimulating hormone and a

35 els of total thyroxine, free thyroxine, free triiodothyronine, and thyroid-stimulating hormone were m

36 '-diiodothyronine, triiodothyronine, reverse triiodothyronine, and thyroxine.

37 cal levels of active thyroid hormone (3,3',5-triiodothyronine) are controlled by the action of activa

38 ropin and the thyroid hormones thyroxine and triiodothyronine) are sometimes used as indicators of io

39 those for the thyroid hormones thyroxine and triiodothyronine, are among the clinical procedures for

40 The total number of triiodothyronine binding sites per nucleus was similar i

41 We observed that the addition of triiodothyronine-bound recombinant TRbeta or a ligand bi

42 D3), which inactivates thyroxine and 3,3', 5-triiodothyronine by 5-deiodination.

43 id produced a more rapid rise in total serum triiodothyronine concentration and a higher total peak s

44 Triiodothyronine concentration in plasma decreases durin

45 concentration and a higher total peak serum triiodothyronine concentration than the other products,

46 GH significantly decreased serum total triiodothyronine concentrations and IGF-I significantly

47 g TRbeta2 to recruit coactivator at limiting triiodothyronine concentrations.

48 the extract of the coactivator function in a triiodothyronine-dependent manner and markedly impaired

49 second included four studies and showed that triiodothyronine did not add hemodynamic benefits versus

50 Thyroxine and reverse triiodothyronine (EC(50) levels approximately 1 nm) were

51 In vitro exposure of immature islets to triiodothyronine enhanced the expression of Mafa, the se

52 -stimulating hormone, total thyroxine, total triiodothyronine, free thyroxine, free triiodothyronine,

53 eptin significantly increased levels of free triiodothyronine, free thyroxine, insulin-like growth fa

54 l for the intracellular production of 3,5,3'-triiodothyronine from thyroxine.

55 Significant effects on plasma free triiodothyronine (FT3) concentrations occurred with expo

56 RL), thyroid stimulating hormone (TSH), free triiodothyronine (fT3), and free thyroxin (fT4) were mea

57 Cord blood levels of free triiodothyronine (FT3), FT4, TSH, and TPOAb were measure

58 nergy expenditure, percentage body fat, free triiodothyronine (FT3), urinary norepinephrine, and plas

59 xylic acid, 3,3',5'-triiodothyronine, 3,3',5-triiodothyronine, gentisate, rosmarinate, and 3-nitrotyr

60 A single large dose of L-triiodothyronine given to hypothyroid rats caused a 4.7-

61 nt elevations in both tetraiodothyronine and triiodothyronine hormones.

62 nuclear in both the absence and presence of triiodothyronine; however, triiodothyronine induced a nu

63 hydrocortisone + placebo group 167 +/- 286; triiodothyronine + hydrocortisone group 466 +/- 495; p =

64 placebo, 3) hydrocortisone + placebo, or 4) triiodothyronine + hydrocortisone.

65 to any changes in plasma cortisol, insulin, triiodothyronine, IGF-1 or glucose.

66 1 nm) were >100-fold more potent than 3,5,3'-triiodothyronine in initiating vesicle binding to actin

67 id inactivation of circulating thyroxine and triiodothyronine in patients with hemangiomas and its bl

68 le for D2 in the generation of plasma 3,5,3'-triiodothyronine in this species.

69 weight loss, whereas serum concentrations of triiodothyronine increased significantly (by approximate

70 Serum concentrations of reverse triiodothyronine increased significantly during and afte

71 Instead, triiodothyronine increased sirtuin-1, fibrillin-1, proli

72 e and presence of triiodothyronine; however, triiodothyronine induced a nuclear reorganization of TRb

73 nd fasting blood biochemistry indexes (total triiodothyronine, insulin, leptin, and ghrelin) as indep

74 by this gene appears to be the transport of triiodothyronine into neurons.

75 thyroxin to the biologically active 3,5, 3'-triiodothyronine, is highly concentrated in a group of s

76 is needed to allow for steady delivery of L-triiodothyronine" (it currently reads "... for steady de

77 5-Triiodothyronine (L-T3) given to intact mice produced a

78 es for muscimol in the presence of 3,3', 5-L-triiodothyronine (L-T3) indicated a noncompetitive inhib

79 erefore examined the effects of TH (L-3,3',5-triiodothyronine, L-T3) given to TH-deprived and to inta

80 Steroids alone and steroids plus triiodothyronine/l-thyroxine also significantly reduced

81 red and, when the latter is normal, the free triiodothyronine level should be obtained.

82 here were also no differences in circulating triiodothyronine levels between groups at the end of the

83 Triiodothyronine levels decrease in infants and children

84 Plasma triiodothyronine levels increased to supraphysiological

85 Serum triiodothyronine levels were elevated, but only in anima

86 -stimulating hormone and a decrease in serum triiodothyronine levels.

87 e prohormone thyroxine to the active hormone triiodothyronine, modifying the expression of approximat

88 olus and infusions of vasopressin and either triiodothyronine or L-thyroxine.

89 olus and infusions of vasopressin and either triiodothyronine or l-thyroxine.

90 rum concentrations of total thyroxine, total triiodothyronine, or free thyroxine index.

91 there is a perception that adding synthetic triiodothyronine, or liothyronine, to levothyroxine impr

92 total triiodothyronine, free thyroxine, free triiodothyronine, parathyroid hormone, prolactin, N-term

93 mug/kg; placebo + placebo group 208 +/- 392; triiodothyronine + placebo group 501 +/- 370; hydrocorti

94 hour IV infusion of 1) placebo + placebo, 2) triiodothyronine + placebo, 3) hydrocortisone + placebo,

95 Thyroid hormone (T3 or 3,5,3'-triiodothyronine) plays a causative role during amphibia

96 ue reveals a novel mechanism for controlling triiodothyronine production that provides the first exam

97 Cluster analysis of triiodothyronine-regulated gene expression among 19 diff

98 igation and puncture, with or without 3,5,3'-triiodothyronine replacement (3 ng/hr), or sham surgery.

99 hyroid-stimulating hormone (TSH), thyroxine, triiodothyronine resin uptake, and free thyroxine index

100 In previous work, we characterized a 3,5,3'-triiodothyronine response element (T3RE) in acetyl-CoA c

101 siently transfected with plasmids containing triiodothyronine response elements and a minimal promote

102 ganded TR.RXR recruits both complexes to the triiodothyronine-responsive region of growth hormone gen

103 isoform is mainly limited to the pituitary, triiodothyronine-responsive TRH neurons, the developing

104 circulating concentrations of thyroxine and triiodothyronine returned to pre-weight-loss levels.

105 ence or absence of cycloheximide or 3,3', 5'-triiodothyronine (reverse T3, rT3) in rat pituitary tumo

106 values of 75-100 microM included 3,3', 5'-l-triiodothyronine (reverse T3; r-T3), 3,3'-diiodo-L-thyro

107 ta: L-triiodothyronine, TH, TH receptor, and triiodothyronine (reverse) were inferred as upstream reg

108 id hormones, including 3,3'-diiodothyronine, triiodothyronine, reverse triiodothyronine, and thyroxin

109 was derived from the T4 metabolite, reverse triiodothyronine (revT3), while functional studies provi

110 to 3,5,3'-triiodothyronine (T3) and 3,3',5'-triiodothyronine (rT3) by the outer- and inner-ring deio

111 increase in rat HCN2 mRNA is likely due to L-triiodothyronine stimulation of HCN2 gene transcription.

112 ee thyroxine, but not the minimal isoform of triiodothyronine, suggesting that chronic anti-VEGF trea

113 In vivo neonatal triiodothyronine supplementation and TH inhibition, resp

114 3,5,3'-triiodothyronine supplementation appeared to increase la

115 All were conducted with triiodothyronine (T(3)) and a tricyclic antidepressant.

116 f acute illness, namely a decrease in 3,5,3'-triiodothyronine (T(3)) and thyroid-stimulating hormone

117 compared the effectiveness of lithium versus triiodothyronine (T(3)) augmentation as a third-step tre

118 of pRb and compared the effects of E(2) and triiodothyronine (T(3)) on these phenomena.

119 The thyroid hormones thyroxine (T(4)) and triiodothyronine (T(3)) play key roles in regulating dev

120 n between SREBP-1c, nuclear factor Y, 3,5,3'-triiodothyronine (T(3)) receptors, and co-activators usi

121 on the one hand, and by thyroxine (T(4)) and triiodothyronine (T(3)) replacement on the other.

122 Triiodothyronine (T(3)) supplementation may be a useful

123 expression of target genes in the absence of triiodothyronine (T(3)) through the recruitment of the c

124 Administration of 3,5,3'-triiodothyronine (T(3)) to rats resulted in an increase

125 ealthy adults before and after three days of triiodothyronine (T(3)) treatment.

126 T(4) is enzymatically deiodinated to 3,5,3'-triiodothyronine (T(3)), a high-affinity ligand for the

127 g hormone (TSH), free thyroxine (T(4)), free triiodothyronine (T(3)), and leptin concentrations were

128 composition (by hydrostatic weighing), serum triiodothyronine (T(3)), and reverse T(3) (rT(3)).

129 nown, highly potent physiological TR ligand, triiodothyronine (T(3)), and with a synthetic TR antagon

130 effects of administering a primary mitogen, triiodothyronine (T(3)), at the time of 70% partial hepa

131 Triiodothyronine (T(3)), the bioactive form of thyroid h

132 T(4)) to the active form of thyroid hormone, triiodothyronine (T(3)).

133 ear receptors (TRs alpha and beta) that bind triiodothyronine (T(3), 3,5,3'-triiodo-l-thyronine) with

134 n whom T(4) replacement was stopped (without triiodothyronine [T(3)] replacement) in preparation for

135 we evaluated the ability of thyroid hormone (triiodothyronine [T(3)]), a known hepatic mitogen, to st

136 Thyroid hormone (3,5,3'-triiodothyronine; T(3)) is essential for normal developm

137 The effects of triiodothyronine (T3 ), insulin and leptin on beta cell

138 pe 2 deiodinase (D2), which generates 3,5,3'-triiodothyronine (T3 ), the active thyroid hormone.

139 (10 mU ml(-1)), thyroxine (T4) (100 nM), and triiodothyronine (T3) (100 pM) alter intrafollicular mit

140 Ralpha and TRbeta plays an important role in triiodothyronine (T3) action and TR isoform specificity.

141 Triiodothyronine (T3) activates rat liver S14 gene trans

142 e the conversion of thyroxine (T4) to 3,5,3'-triiodothyronine (T3) and 3,3',5'-triiodothyronine (rT3)

143 erapy results in relatively low serum 3,5,3'-triiodothyronine (T3) and high serum thyroxine/T3 (T4/T3

144 ents with a poor outcome had lower levels of triiodothyronine (T3) and higher thyroxine (T4).

145 and cardiac abnormalities were alleviated by triiodothyronine (T3) and T4 administration to pups, by

146 Serum triiodothyronine (T3) and thyroxine (T4) concentrations

147 on the effects of Hg on the thyroid hormones triiodothyronine (T3) and thyroxine (T4) in aquatic wild

148 congeners, total and free thyroid hormones (triiodothyronine (T3) and thyroxine (T4)), thyroid-stimu

149 levels were associated with lower cord total triiodothyronine (T3) and total T4 levels, and maternal

150 evels of thyroid hormones thyroxine (T4) and triiodothyronine (T3) averaged 46.9 and 64%, respectivel

151 ecruitment in vitro, while preserving normal triiodothyronine (T3) binding and CoR interactions.

152 When triiodothyronine (T3) binds the thyroid hormone receptor

153 upon the prereceptor regulation of supply of triiodothyronine (T3) by deiodinase enzymes.

154 Triiodothyronine (T3) causes a 30-fold increase in trans

155 ly in life, D3KO mice exhibit delayed 3,5,3'-triiodothyronine (T3) clearance, a markedly elevated ser

156 e report that despite a normal plasma 3,5,3'-triiodothyronine (T3) concentration, cold-exposed mice w

157 ate of adrenergic overactivity prevails when triiodothyronine (T3) concentrations become excessive, t

158 changes in gene expression and plasma 3,3',5-triiodothyronine (T3) concentrations in tadpoles treated

159 nd ligand-binding protein to decrease T4 and triiodothyronine (T3) cross-reactivity with the antibody

160 eir wild-type counterparts were treated with triiodothyronine (T3) for 14 days and compared to untrea

161 e of a critical role for the thyroid hormone triiodothyronine (T3) in controlling the maturation and

162 thyroxine (T4) to the active hormone 3,5,3'-triiodothyronine (T3) in peripheral tissues.

163 sor thyroxine (T4) to the active form 3,5,3'-triiodothyronine (T3) in the blood is many times higher

164 Treatment of endothelial cells with L-3,5,3'-triiodothyronine (T3) increased the association of TRalp

165 ed to determine if fetal plasma cortisol and triiodothyronine (T3) influenced the mRNA abundance of U

166 We have discovered that 3,3',5-triiodothyronine (T3) inhibits binding of a PIP-box sequ

167 Thyroidal production of triiodothyronine (T3) is absent in athyreotic patients,

168 3,3',5-Triiodothyronine (T3) is an important diagnostic marker

169 Although 3,5,3'-triiodothyronine (T3) is considered to be the primary bi

170 Plasma cortisol and total triiodothyronine (T3) levels increased towards term, wer

171 by growth in serum-free medium with varying triiodothyronine (T3) levels.

172 The thyroid hormone l-3,3',5-triiodothyronine (T3) plays an important role during cer

173 Triiodothyronine (T3) regulates key metabolic processes

174 a (ACCalpha) promoter 2 that mediated 3,5,3'-triiodothyronine (T3) regulation of ACCalpha transcripti

175 on of the human N-Tera-2 (NT2) cell line, in triiodothyronine (T3) replete and T3-depleted media.

176 We tested the primary hypothesis that triiodothyronine (T3) repletion is safe in this populati

177 sal silencing of genes that contain positive triiodothyronine (T3) response elements.

178 e expression of target genes upon binding to triiodothyronine (T3) response elements.

179 roteins decreased by 50%, and treatment with triiodothyronine (T3) restored ubiquitination to control

180 Addition of the thyroid hormone 3,5,3'-L-triiodothyronine (T3) resulted in reversal of this repre

181 Triiodothyronine (T3) stimulates a 7-fold increase in tr

182 Triiodothyronine (T3) stimulates a robust increase (>40-

183 yroxine (T4) and supplies most of the 3,5,3'-triiodothyronine (T3) that is essential for brain develo

184 roid hormone in the circulation, into 3,5,3'-triiodothyronine (T3) the major ligand for TRs.

185 nase thought to provide intracellular 3,5,3' triiodothyronine (T3) to a restricted group of tissues.

186 efined sleep of acute restoration of l-3,3'5-triiodothyronine (T3) to a sleep-regulatory brain region

187 rk has shown that acute microinjections of l-triiodothyronine (T3) to the preoptic region significant

188 er cone loss) were used to determine whether triiodothyronine (T3) treatment (stimulating TH signalin

189 me (NTIS), characterized by low serum 3,5,3'-triiodothyronine (T3) with normal l-thyroxine (T4) level

190 range and levels of free thyroxine (FT4) and triiodothyronine (T3) within the reference range are com

191 hyroid histology, plasma thyroxine (T4), and triiodothyronine (T3), and hepatic outer ring deiodinati

192 Thyrotropin (TSH), total triiodothyronine (T3), and thyroxine (T4) were measured

193 to the metabolically active molecule 3,5,3'-triiodothyronine (T3), but its global inactivation unexp

194 hed when the normal prepartum rise in plasma triiodothyronine (T3), but not cortisol, was prevented b

195 BDEs were not strongly associated with total triiodothyronine (T3), free T4, or thyroid-stimulating h

196 condition, antibody response to vaccination, triiodothyronine (T3), hepatic biotransformation (7-etho

197 nstrate a negative role of one such hormone, triiodothyronine (T3), in triggering the differentiation

198 Addition of the ligand, 3,5,3'-triiodothyronine (T3), induces transcriptional repressio

199 In mouse myocyte cultures, triiodothyronine (T3), norepinephrine (NE) through a bet

200 issues convert the prohormone thyroxine into triiodothyronine (T3), the active ligand for the thyroid

201 (D2) that activates thyroxine (T4) to 3,3',5-triiodothyronine (T3), the disruption of which (Dio2(-/-

202 Here, we show that the thyroid hormone triiodothyronine (T3), through binding to its nuclear re

203 serum thyrotropin-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and free T4 conce

204 The thyroid hormones triiodothyronine (T3), thyroxine (T4), and thyrotropin (

205 ulin), which contain both thyroxine (T4) and triiodothyronine (T3), were the first pharmacologic trea

206 The thyroid hormone triiodothyronine (T3), which antagonizes TRH action in t

207 DIO2 converts thyroxine (T4) to triiodothyronine (T3), which binds to the TH receptor, w

208 (as studied in several laboratories), and by triiodothyronine (T3), which has not been previously exa

209 ter-transcription factor (COUP-TF) represses triiodothyronine (T3)-dependent transcriptional activati

210 ted dominant negative activity as it blocked triiodothyronine (T3)-mediated transcriptional activity

211 assays showed that TRalpha failed to support triiodothyronine (T3)-stimulated transcription on "inact

212 o hepatocytes is stimulated about 30-fold by triiodothyronine (T3).

213 iological effects of thyroid hormone, 3,5,3'-triiodothyronine (T3).

214 rget genes whose expression are decreased by triiodothyronine (T3).

215 ession only in the presence of its ligand, L-triiodothyronine (T3).

216 ts elicited by the thyroid hormone, 3,5,3'-L-triiodothyronine (T3).

217 mmunosensor was constructed to detect 3,3',5-triiodothyronine (T3).

218 primarily tetraiodothyronine (T4), and some triiodothyronine (T3).

219 rmone by converting thyroxine (T4) to 3,5,3'-triiodothyronine (T3).

220 oxine (T4) to the physiologically active TH, triiodothyronine (T3).

221 Thyroid hormone [triiodothyronine (T3)] positively regulates NADPH cytoch

222 ial organ donor can include thyroid hormone (triiodothyronine [T3] or levothyroxine [T4]), corticoste

223 yme that inactivates thyroid hormone (3,5,3' triiodothyronine [T3]), is frequently expressed by tumor

224 ter is responsive to thyroid hormone (3,3',5-triiodothyronine, T3) and efficiently repressed by unlig

225 dels with a hyperthyroid-like phenotype, TH (triiodothyronine, T3), in culture and exercise in vivo.

226 localized regulation of levels of active TH (triiodothyronine, T3), through spatiotemporal expression

227 homeostasis in response to thyroid hormone (triiodothyronine, T3).

228 rates with PGC-1alpha to enhance response to triiodothyronine, T3.

229 ial sequence of the thyroid hormone (3,5, 3'-triiodothyronine; T3) receptor.

230 sion of more than 43% of positive T3 (3,3',5-triiodothyronine) targets in hypothyroid mice.

231 and functions were inferred from the data: L-triiodothyronine, TH, TH receptor, and triiodothyronine

232 ned more non-thyroglobulin-associated T4 and triiodothyronine than did those in wild-type mice, indep

233 ne, which undergoes peripheral conversion to triiodothyronine, the active form of thyroid hormone.

234 wing ligands: deoxycholate, 5-leuenkephalin, triiodothyronine, thyronine, dabsyl-L-valine, and N-benz

235 Circulating triiodothyronine, thyroxine, and glucagon concentrations

236 genous and xenobiotic compounds, including L-triiodothyronine, thyroxine, estrone, p-nitrophenol, 2-n

237 on is achieved through the binding of 3,5,3'-triiodothyronine to its nuclear receptor, which results

238 paper, we demonstrate that binding of TH T3 (triiodothyronine) to THRB induces senescence and deoxyri

239 enuated by cotransfection of TR alpha 1 plus triiodothyronine treatment.

240 s between BDE-47 and maternal total and free triiodothyronine (TT3 and FT3).

241 circulating total thyroxine (TT4) and 3,5,3'-triiodothyronine (TT3), respectively, while TT4 and TT3

242 free thyroxine [TT4 and FT4], total and free triiodothyronine [TT3 and FT3], thyroid-stimulating horm

243 hy men treated for 14 days with 75 microg of triiodothyronine, using 24,000 cDNA element microarrays.

244 Similarly, mean triiodothyronine values ranged from 156.18 to 195.13 ng/

245 ty acid synthase gene by the thyroid hormone triiodothyronine, various constructs of the human fatty

246 accelerating the conversion of thyroxine to triiodothyronine via type 2 deiodinase in mouse skeletal

247 No change in levels of serum thyrotropin or triiodothyronine was detected, although the thyroxine le

248 rast, the decline of TSH by treatment with L-triiodothyronine was severely blunted in SRC-1(-/-) mice

249 Triiodothyronine was significantly higher in the ISP90 g

250 However, removal of cortisol and triiodothyronine was similar to removal of cytokines.

251 ine excretion and in serum concentrations of triiodothyronine were significantly correlated with perc

252 r binding activities, putative receptors for triiodothyronine, were detected after incubation of horm

253 and propionic acid analogs of thyroxine and triiodothyronine, which are inseparable by currently ava

254 id, the prohormone thyroxine is converted to triiodothyronine, which is essential in brain developmen

255 lysates activate thyroxine (T(4)) to 3,5,3'-triiodothyronine with typical characteristics of D2 such

256 ine the safety and efficacy of administering triiodothyronine, with and without hydrocortisone, in a

257 A 24-hour infusion of triiodothyronine, with or without hydrocortisone, in an